SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is gaining significant market attention as traders react to major quantum executive orders, ongoing Russell 3000 index inclusion momentum, and a series of high-profile government-linked events. The community is actively debating the company's valuation versus peers and discussing its long-term potential as a key player in the quantum computing and sensing space.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing heightened investor attention driven by strong momentum in the weight-loss peptide space and analyst upgrades that highlight its growth potential. The community is actively debating the company's long-term platform shift toward a broader healthcare ecosystem while keeping a close eye on the upcoming FDA advisory meeting as a potential fundamental catalyst.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is facing intense bearish pressure and downward momentum as investors grapple with a significant valuation reset, compounded by concerns over contract losses in Europe and broader weakness in the software sector. While the community remains deeply polarized between long-term bulls highlighting strong defense-sector fundamentals and vocal bears celebrating the stock's recent decline, the active discourse is heavily focused on critical technical support levels and the potential for a bottoming process.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) continues to see heavy investor interest as the semiconductor sector experiences significant volatility, with market participants debating whether the surge in AI-related infrastructure spending represents a sustainable boom or an overextended bubble. While some investors are actively betting against the rally, others are aggressively buying dips, signaling a high-conviction tug-of-war between those focusing on record-breaking growth and those bracing for a potential reversal.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is trending following positive Phase 3 clinical trial results for its depression treatment, triggering a surge in trading volume and investor attention. While some community members celebrate the potential for this breakthrough to reshape mental health care, others remain cautious, expressing significant concerns about the company's historical financial practices, high cash burn rate, and the risk of shareholder dilution.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant attention as investors speculate on potential buyout scenarios and evaluate the company's turnaround efforts under new leadership. The community is actively debating the stock's valuation, high short interest, and dividend sustainability, with many traders looking for a catalyst to drive a price rebound.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following the failure of its Phase 3 SigVig-002 cancer trial, a setback that has intensified community frustration regarding the company's recent acquisition strategy and leadership. Despite the negative clinical news, investors are actively debating the company's long-term oncology pipeline and the potential for M&A activity in the sector, while others remain focused on the stability offered by the dividend yield.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing downward pressure amid broader hyperscaler concerns over AI infrastructure spending, with investors closely watching Prime Day as a gauge for consumer health. While the community is debating the stock's valuation versus its massive capital expenditure, many remain focused on the long-term potential of AWS and the company's aggressive push into custom AI silicon.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending following a massive sell-off triggered by an FDA rejection of its lead SCA treatment, though heavy institutional and insider buying has since sparked significant volatility and retail interest in potential recovery plays. Investors are now closely monitoring the company's reprioritized clinical pipeline, specifically upcoming data on epilepsy and degrader assets, as the stock attempts to find a floor.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is experiencing significant volatility and trending higher as investors aggressively position themselves into the memory and data storage sector, which is increasingly viewed as a critical bottleneck for AI infrastructure. Market participants are actively discussing the stock's parabolic run, debating the sustainability of current valuation levels, and closely monitoring price target hikes alongside institutional rotation into the memory supply chain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS

Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States...

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements...

Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports First Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $6.23, for a total value of $103,835.41. Following the sale, the insider directly owned 1,193,173...

Xeris Biopharma (XERS) to Release Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-xeris-pharmaceuticals-inc-stock...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) has earned an average rating of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy r...

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL trimmed its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 83.1% during the third quarter, according to its most recent filing with the Securities...

Apella Capital LLC Acquires 235,897 Shares of Xeris Biopharma Holdings, Inc. $XERS

Apella Capital LLC increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 2,359.0% during the fourth quarter, according to the company in its most recent...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.90
Prev Close	$6.95
Open	$6.98
Dividend Yield	0.00%
50-Day Moving Average	$6.29
Beta	1.25
Avg. Volume	1.79M
PE Ratio	105.34

52-Week High	$10.08
52-Week Low	$4.52
Market Capitalization	$1.2B
EPS (Annual)	$0.0032
Price to Book	91.51
Revenue Per Employee	$670,908.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

XERSXeris Biopharma Holdings Inc

Latest XERS News